| Literature DB >> 36003616 |
Xiamin Cheng1, Hui Yan1, Songhao Pang1, Mingjun Ya1, Feng Qiu1, Pinzhu Qin2, Chao Zeng3, Yongna Lu1.
Abstract
Although medicinal natural products and their derivatives have shown promising effects in disease therapies, they usually suffer the drawbacks in low solubility and stability in the physiological environment, low delivery efficiency, side effects due to multi-targeting, and low site-specific distribution in the lesion. In this review, targeted delivery was well-guided by liposomal formulation in the aspects of preparation of functional liposomes, liposomal medicinal natural products, combined therapies, and image-guided therapy. This review is believed to provide useful guidance to enhance the targeted therapy of medicinal natural products and their derivatives.Entities:
Keywords: liposome; nano-carrier; natural product; targeted-delivery; traditional Chinese medicine
Year: 2022 PMID: 36003616 PMCID: PMC9393238 DOI: 10.3389/fchem.2022.963004
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.545
FIGURE 1Typical structure of liposome.
Liposomal natural products and their derivatives.
| Drug | Source | Lipid composition | Size/nm | Bioactivity | Ref |
|---|---|---|---|---|---|
| Artemisinin |
| Free | N.A. |
|
|
| P90G, CHOL | 136.2 ± 42.27 |
| |||
| PEG2000, P90G, CHOL | 132.6 ± 8.78 |
| |||
| L-α-phosphatidylcholine, CHOL | 79 ± 5 | IC50: 6.0 ± 1.4 μg/ml for intracellular |
| ||
| ADP109 | Artemisinin | Free | N.A. | IC50: 0.07 ± 0.01 μM to BT474 cells; IC50: 10 ± 3 μM to MDA-MB231 cells |
|
| EPC | 70 ± 20 | IC50: 0.08 ± 0.01 μM to BT474 cells; IC50: 7 ± 2 μM to MDA-MB231 cells | |||
| AMPm109 | Artemisinin | Free | N.A. | IC50: 1.3 ± 0.8 μM to BT474 cells; IC50: >> 100 μM to MDA-MB231 cells |
|
| EPC | 50 ± 20 | IC50: 1.3 ± 0.4 μM to BT474 cells; IC50: >> 20 μM to MDA-MB231 cells | |||
| Baicalin |
| HSPC, CHOL, F-PEG-CHEMS | 68.4 ± 3.6 | IC50: 58.3 ± 3.3 μg/ml to HeLa Cells |
|
| HSPC, CHOL, PEG-CHEMS | 70.9 ± 1.4 | IC50: 76.1 ± 4.6 μg/ml to HeLa Cells | |||
| HSPC, CHOL | 87.6 ± 1.6 | IC50: 78.8 ± 4.2 μg/ml to HeLa Cells | |||
| Free | N.A. | IC50: 64.6 ± 3.8 μg/ml to HeLa Cells | |||
| BDMC |
| D-α-tocopherol polyethylene glycol 1000 succinate (TPGS or vitamin E TPGS), CHOL, mixlecithin | 75.98 ± 5.46 | Effective analgesic activity due to prolonged latency time, and the significantly decreased level of uric acid |
|
| Betulinic acid |
| Egg phosphatidylcholine, egg phosphatidylglycerol | 1000–1500 | Efficiently inhibited human colon and lung tumors in nude mice |
|
| Borneol |
| Phospholipid, CHOL | 167.1 | BO upregulates drug effect and synergistically help the BA to promote the recovery of the brain by inhibiting neuronal cell damage and apoptosis |
|
| Breviscapine |
| HSPC: CHOL, Pluronic P85 | 118.8 ± 4.9 | Significantly increased absorption in Caco-2 cells and oral bioavailability in rats |
|
| PC, PG, CHOL, triolein or tricaprylin | 17,900 | bre-MVL significantly prolonged the retention both |
| ||
| PC, CHOL | 540 | ||||
| BP |
| LPPC | 200–280 | Liposomal BP showed higher cytotoxicity to B16/F10 melanoma cells than free BP by arresting cell cycle at G0/G1 phase |
|
| Camptothecin (CPT) | O | Single/two/three components of EPC, DOTAP, DPPG, DLPC, DMPG, DOPC, DOPE, DMPE-DTPA, DPPC, DMPC, CHOL | 30–35 | Liposomal CPT improved the circulated time in mouse, compared with free CPT. |
|
| Chlorophyll |
| Soybean lecithin, CHOL | 21.7 ± 6.0 | Significantly improved the water solubility of lipophilic chlorophyll and its NIR fluorescence |
|
| Curcumin |
| Free | N.A. | EC50: 1.9 and 1.5 μM to colon and lung cancer cells, respectively |
|
| EggPC, CHOL, DSPE-PEG | ∼420 | EC50: 0.96 and 0.90 μM to colon and lung cancer cells, respectively | |||
| EggPC, CHOL, DSPE-PEG (βCD-C) | ∼420 | EC50: 3.25 and 2.9 μM to colon and lung cancer cells, respectively | |||
| Curcumol |
| Yolk lecithin, CHOL | <200 nm | Gal-s modified liposome enhanced the targeted delivery and treatment to liver cancer cells |
|
| Daunorubicin |
| DSPC, CHOL | 45 | Improved plasma half life and uptake by tumor |
|
| Docetaxel |
| Soybean phospholipids, CHOL | ∼90 nm | GA-modified liposomes enhanced hepatocytes-target cellular uptake by receptor-mediated endocytosis |
|
| Doxorubicin |
| HSPC, CHOL, MPEG-DSPE | <100 | AIDS-related Kaposi’s sarcoma; ovarian cancer resistant to paclitaxel and platinum |
|
| EPS |
| Soybean phospholipid, CHOL, tocopherol | 200 | The liposomal EPS significantly improved the immune response to Newcastle disease vaccine |
|
| Ganoderic acid |
| P90G | 150–180 | Liposomal ganoderic acid has shown better antitumor effects by inhibiting various signaling pathways |
|
| Ginsenoside |
| EYPC, CHOL | 60.54 ± 1.78 | The three ginsenoside-modifications enhanced the cellular uptake mediated by GLUT carriers |
|
| 52.02 ± 1.42 | |||||
| 99.02 ± 2.55 | |||||
| Hirudin |
| DSPC, BC | 191.49 ± 3.67 | Inhibited the expression of VEGF and TGF-β1 in the rat kidneys |
|
| Honokiol |
| PC, cholesterol, PEG4000 | 130 ± 20 | Liposomal honokiol significantly suppressed Lewis lung carcinoma overexpressing VEGF-D by inhibiting the tumor-associated lymphangiogenesis and metastasis |
|
| Idarubicin | — | DSPC, DSPE-PEG2000 | 100 ± 30 | Enhanced the circulation longevity of idarubicin to improve antitumor activity |
|
| Juglone |
| DPPC, CHOL | 187 ± 12 | The temperature-sensitive liposomes significantly inhibited HepG2 cell growth and proliferation upon exposed to hyperthermia |
|
| 220 ± 32 | |||||
| LBP |
| Soybean phospholipids, CHOL | 121.5 ± 0.2 | The LBPL-OVA vaccine formulation enhanced immune responses |
|
| 121.13 ± 0.37 | |||||
| Matrine |
| HSPC, CHOL, DSPE-mPEG2000, DSPE-PEG-MAL, | 97.59 ± 1.93 | RGD-M-LCL significantly improved the tumor-specificity and suppressed the proliferation of Bcap-37, HT-29 and A375 cells, compared with matrine alone |
|
| Morphine |
| HSPC, mPEG-DSPE, CHOL | 120.45 ± 10.53 | Prolong analgesic effect and reduce drug addiction |
|
| OP |
| Soybean phospholipid, CHOL | 245.3 | Liposomes significantly improved the immune-enhancing activity of OP on Kupffer cells |
|
| Soybean phospholipid, CHOL | 245.3 | Liposomes significantly improved the immune-enhancing activity of OP against Newcastle disease virus on chicken |
| ||
| Soybean phospholipid, CHOL | 245.3 | Liposomal OP significantly activated mouse peritoneal macrophages |
| ||
| Soybean phospholipid, CHOL | 245.3 | Liposomal OP significantly enhanced the antioxidative and immunoregulatory activities of OP in ICR mice |
| ||
| Paclitaxel |
| Free | N.A. | IC50: 42.38 ± 2.4 and 14.71 ± 1.37 nmol/L to SKOV-3 cells and HUVECs, respectively |
|
| DPPC, DSPG, MPPC, DSPE-PEG | 80.2 ± 3.9 | IC50: 31.19 ± 2.02 and 11.51 ± 1.13 nmol/L to SKOV-3 cells and HUVECs, respectively | |||
| DPPC, DSPG, MPPC, DSPE-PEG, DSPE-PEG-K237 | 88.3 ± 4.7 | IC50: 13.61 ± 1.81 and 5.54 ± 0.95 nmol/L to SKOV-3 cells and HUVECs, respectively | |||
| DSPE-PEG2000-Tn, DPPC | 74 ± 0.36 | IC50: 1.93 nM to HepG-2 cells |
| ||
| Parthenolide |
| SPC | 118.6 ± 0.2 | PTL-Lips enhanced the antitumor efficacy |
|
| PPa | Terrestrial and marine plants, insect fluid | DPPC, CHOL, DSPE-mPEG5k | 100 | Significantly improved the water solubility, prolong blood circulation and the bio-distribution in mice |
|
| PpIX | Living cells | PC | 124 ± 0.85 | IC50: 0.53 ± 0.19 µM to Hela cells |
|
| RGP |
| Soybean phospholipid, CHOL, Tween-80 | 170.83 ± 2.08 | The positive modulation effects on dendritic cells |
|
| 193.57 ± 1.89 | |||||
| Resveratrol |
| Soybean lecithin, CHOL | 146–585 | Liposomal resveratrol showed neuroprotective effects on mitochondria in substantia nigra cells of Parkinsonized rats |
|
| Sal B |
| PEG2000(18:0/18:0), P90G, CHOL | 140.0 ± 6.5 | The PEGylated liposome improved the antihyperalgesic effect by prolonged time |
|
| Topotecan | Synthetic analog of camptothecin | Sphingomyelin, CHOL | 100 ± 20 | The formulation enhanced the half-life in plasma |
|
| Triptolide |
| TRX-20, HSPC, PEG5000-PE | 117.9 ± 1.4 | Significantly improved the anti-inflammatory effects in membranous nephropathic model |
|
| Vincristine |
| DSPC, CHOL | 100 | Prolonged retention time dramatically improved the therapeutic effects on mice bearing P388 murine leukemia |
|
| Wogonin |
| Free | NA | IC50: 16.248 mg ml−1 to HepG2 cells |
|
| Soybean phospholipids, CHOL | 87.4 ± 4.8 | IC50: 3.344 mg ml−1 to HepG2 cells | |||
| Soybean phospholipids, CHOL, 18-GA-Suc | 90.5 ± 2.2 | IC50: 2.292 mg ml−1 to HepG2 cells |
FIGURE 2Liposomal artemisinin and its analogs.
FIGURE 3Liposomal polyphenolic compounds.
FIGURE 4Liposomal lactones.
FIGURE 5Liposomal terpenoids.
FIGURE 6Liposomal alkaloids.
FIGURE 7Liposomal flavonoids.
FIGURE 8Other liposomal natural products.
FIGURE 9Liposomal porphyrinoids.
FIGURE 10The preparation of miR497/TP-HENPs and the mechanism of combined therapies: chemotherapy with miRNA therapy. Triptolide (TP).
FIGURE 11The preparation of TP/Ce6-LP and the mechanism of combined therapies: chemotherapy with PDT.
FIGURE 12The preparation of ICG-PTL-Lips@MNPs and the mechanism of combined therapies: chemotherapy with PTT.
FIGURE 13The preparation of F7-TPT-TSL and the mechanism of combined therapies: dual chemotherapies with hyperthermia therapy.
FIGURE 14The preparation of GOD-PTL-Lips@MNPs and the mechanism of combined therapies: chemotherapy with starvation and CDT.
FIGURE 15(A) Imaging contrast agents. (B) FLI of BGC-823 tumor-bearing mice after i.v. injection of DiR-labeled C-lipo and ginsenoside liposomes (C-lipo, Rh2-lipo, Rg3-lipo, and Rg5-lipo). Reproduced (Adapted) under the terms of the Creative Commons Attribution (CC BY-NC 4.0) (Hong et al., 2019). Copyright 2019, Theranostics. (C) SPECT imaging of SCCHN tumor-bearing nude rats after i.v. injection of 99mTc-Gd-liposomes. Reprinted (adapted) with permission (Li et al., 2012b). Copyright 2012, American Chemical Society. (D) MR images of after i.v. injection of sonosensitive gadoteridol- and doxorubicin-loaded liposomes. Reproduced (Adapted) under Creative Commons Attribution License (CC BY) (Shi et al., 2015). Copyright 2020, Patrucco and Terreno; (E) PA images after i.v. injection of free ICG and DOX@GdMSNs-ICG-TSLs. Reprinted (adapted) with permission (Sun et al., 2018). Copyright 2018, American Chemical Society. (F) PET Images of 4T1 tumor-bearing mice with low 89Zr-NRep uptake (mouse A, left) and high 89Zr-NRep uptake (mouse B, right) after i.v. injection. Reproduced (Adapted) under Creative Commons Attribution License (CC BY) (Pérez-Medina et al., 2016). Copyright 2016, Mulder and Reiner et al. (G), PET-CT imaging of a B6CBAF1 mouse after i.v. injection of [52Mn]Mn-DOXIL. Reproduced (Adapted) with permission (Gawne et al., 2018). Copyright 2018, Royal Society of Chemistry. The yellow arrow indicated tumors. Red arrowhead indicated the outside reference standard.